Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
GLP-1 receptor agonist inhibited proinflammatory monocyte chemoattractant protein-1 secretion from human atherosclerotic plaque samples and monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor- (TNF-), and interleukin (IL)-1 secretion from human macrophages after ex vivo treatment
Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol Head Neck Surg
Non-fragmentable Linker 3.1 Based on PEG (Polyethylene Glycol) type fragments The cleavage of the non-fragmentable Linker and the release of the drug do not depend on the differences between plasma and cytoplasm
More about this Pin , &
How much can I earn
The market for these therapies is on the brink of major expansion, with projections suggesting that the number of GLP-1 patients worldwide will more than double between 2025 and 2029
:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)
